Orion Portfolio Solutions LLC Invests $728,000 in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Orion Portfolio Solutions LLC bought a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 32,109 shares of the life sciences company’s stock, valued at approximately $728,000.

A number of other institutional investors have also added to or reduced their stakes in IART. Nisa Investment Advisors LLC lifted its position in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after acquiring an additional 2,800 shares during the period. PNC Financial Services Group Inc. boosted its stake in Integra LifeSciences by 33.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company’s stock worth $448,000 after buying an additional 4,967 shares in the last quarter. Nordea Investment Management AB increased its holdings in Integra LifeSciences by 4.1% in the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock valued at $2,919,000 after buying an additional 5,032 shares during the period. Choreo LLC raised its stake in shares of Integra LifeSciences by 29.9% in the 4th quarter. Choreo LLC now owns 22,274 shares of the life sciences company’s stock valued at $500,000 after buying an additional 5,123 shares in the last quarter. Finally, Empowered Funds LLC bought a new position in shares of Integra LifeSciences during the 4th quarter worth about $180,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $19.57 on Monday. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $34.79. The firm’s 50-day moving average price is $23.37 and its two-hundred day moving average price is $22.34. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -217.42, a P/E/G ratio of 0.73 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business’s revenue was up 11.5% on a year-over-year basis. During the same period last year, the firm posted $0.89 EPS. On average, equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.